

## BMP7 selective inhibitor

<b>Code</b>	PG-005
<b>MW (Acetate):</b>	2085.29
<b>Purity:</b>	≥95% (HPLC)
<b>Amount:</b>	10 µg



**Formulation:** This vial contains 10 µg of the titled compound, which has been lyophilized from 0.2 µm filtered DMSO solution.

**Reconstitution:** Reconstitute at 100~200 µg/mL in **DMSO**  
Centrifuge the vial before opening.  
**Rinse the inside of the vial thoroughly with DMSO.**  
When further diluting the DMSO solution, we recommend using a buffered solution (e.g., PBS) with a carrier component to prevent peptide adhesion.  
<Example>  
A 100 µg/mL solution can be prepared by reconstituting 10 µg of peptide in 100 µL DMSO.

**Storage:** Store at -20°C or below for the container vial unopened.  
Recommend to use the peptide as quickly as possible after opening and reconstitution.

**Activity:** Measured by its ability to inhibit smad1 phosphorylation induced by BMP4(2.6 ng/mL) or BMP7(157.5 ng/mL) in A549 cell.  
**Expected IC<sub>50</sub> for BMP7 is ~30 ng/mL under this condition.**

**Evaluation Guideline:** PG-005 is expected to exhibit activity comparable to rNoggin at the same molar concentration, approximately 1/11 (ng/mL) of rNoggin. Determine the optimal concentration under your test conditions by testing at least three points around this concentration.



**This product is "For Research Use Only"**